September 21, 2021
|
Outlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference
|
|
September 13, 2021
|
Outlook Therapeutics Presents Positive NORSE THREE Safety Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at EURETINA Virtual 2021 Medical Conference
|
|
September 8, 2021
|
Outlook Therapeutics to Present at H.C. Wainwright 23rd Annual Global Investment Conference
|
|
August 13, 2021
|
Outlook Therapeutics Reports Financial Results for Third Quarter of Fiscal Year 2021 and Provides Corporate Update
|
|
August 11, 2021
|
Outlook Therapeutics to Participate at the H.C. Wainwright Ophthalmology Virtual Conference
|
|
August 3, 2021
|
Outlook Therapeutics Reports Positive Efficacy and Safety Data from Pivotal Phase 3 NORSE TWO Trial of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
|
|
July 7, 2021
|
Outlook Therapeutics Appoints C. Russell Trenary III as President and Chief Executive Officer
|
|
June 14, 2021
|
Outlook Therapeutics Announces Inclusion in the Russell 2000® Index
|
|
June 8, 2021
|
Outlook Therapeutics Reports Completion of Patient Dosing in the ONS-5010 Pivotal Phase 3 NORSE TWO Trial
|
|
May 27, 2021
|
Virtual Clinical Day Recap: Outlook Therapeutics Joined by Drs. Mark Humayun and Firas Rahhal to Discuss Need for FDA-Approved Ophthalmic Bevacizumab and Status of ONS-5010
|
|